Evinacumab

N/A

Report date: 2025/09/28 11:39:48
First In Class

Base Information

Drug NameEvinacumab
Drug Alias NameEvinacumab-dgnbEvkeezaREGN-1500
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAngiopoietin like 3 inhibitors
TargetsAngiopoietin like 3
Therapy Area/IndicationsHomozygous familial hypercholesterolemiaHypertriglyceridemiaHypercholesterolemia +[4] 
Global Approved IndicationsHomozygous familial hypercholesterolemiaHypercholesterolemia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2021/02/11
Country/TerritoryCzechiaCanadaUnited States +[25] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesUltragenyx Pharmaceutical IncRegeneron Pharmaceuticals IncUltragenyx Germany Gmbh
Inactive CompaniesN/A
Active IndicationsHomozygous familial hypercholesterolemiaHypercholesterolemia
Inactive IndicationsHypertriglyceridemiaMetabolic Diseases

Other Information

ATC CodeC10
Related LinksWikipediaDrugBankKEGG